drug
glasdegib
Marketedupdated 4mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying glasdegib
- phase2CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
- phase2Glasdegib for Chronic Graft-Versus-Host Disease
- phase1A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- phase3Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- —Acute Myeloid Leukemia Real World Treatment Patterns
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 29, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 13, 2036compositionUS 10414748
- Apr 13, 2036compositionUS 10414748
- Apr 13, 2036method-of-use (U-3254)US 11168066
- Apr 13, 2036method-of-use (U-3254)US 11168066
- Apr 13, 2036method-of-use (U-3254)US 11891372
- Apr 13, 2036method-of-use (U-3254)US 11891372
- Apr 14, 2029compositionUS 81484012.6y
- Apr 14, 2029compositionUS 81484012.6y
- Jun 29, 2028formulationUS 84315971.8y
- Jun 29, 2028formulationUS 84315971.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that